Skip to main content
HCPCS J7515 · Level II · Part B drug

J7515: cyclosporine (Gengraf, Sandimmune, Neoral), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J7515

Billing unit
25 MG
Cyclosporine oral 25 mg
ASP payment limit
$0.576
October 2026; +4.4% vs July 2026
Practitioner MUE
0
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J7515 is the Level II code for Cyclosporine, oral, 25 mg, billed per 25 MG. The Medicare Part B ASP payment limit for October 2026 is $0.576 per billing unit, up 4.4% from July 2026. The practitioner MUE allows up to 0 units per date of service (MAI 3). Under OPPS it carries status indicator N. Oral drugs under Part B are payable only in the specific statutory categories (for example oral anticancer or antiemetic drugs with a self-administration exception), so the diagnosis and the regimen must match that category. Other HCPCS codes whose descriptor names cyclosporine: J7516 (billed per 250 mg); J7502 (billed per 100 mg). The ASP crosswalk maps 10 NDCs to it, sold as Gengraf, Sandimmune, Neoral by AbbVie Inc., Novartis Pharmaceuticals Corporation, Teva Pharmaceuticals USA, Inc. No current Billing and Coding Article lists J7515, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J7515 at $0.576 per 25 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.552 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J7515
QuarterPayment limitPerCoinsurance
October 2026$0.57625 MG20%
July 2026$0.55225 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 10 NDCs from 6 labelers to J7515. Report the NDC in the claim's drug segment and bill the number of J7515 units that equals the quantity administered divided by 25 MG; the last column gives units per full package.

NDCs that crosswalk to J7515
NDCDrug nameLabelerPackage sizeBilling units / package
00074-3108-32GengrafAbbVie Inc.30 × 130
00078-0240-15SandimmuneNovartis Pharmaceuticals Corporation30 × 130
00078-0246-15NeoralNovartis Pharmaceuticals Corporation30 × 130
00093-9018-65CyclosporineTeva Pharmaceuticals USA, Inc.30 × 130
23155-0837-30CyclosporineHeritage Pharmaceuticals Inc.30 × 130
23155-0838-30CyclosporineHeritage Pharmaceuticals Inc.30 × 160
60505-0133-00CyclosporineApotex Corp30 × 130
60505-4630-03CyclosporineApotex Corp30 × 130
60505-4631-03CyclosporineApotex Corp30 × 160
68084-0879-25CyclosporineAmerican Health Packaging30 × 130

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J7515. For practitioners the limit is 0 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J7515 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services03 Date of Service Edit: ClinicalOral Medication; Not Payable
Facility outpatient hospital903 Date of Service Edit: ClinicalClinical: Data
DME supplier18003 Date of Service Edit: ClinicalCMS Policy

MUE for J7515 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

Medicaid NCCI differs: the 2026 Q4 Medicaid MUE for J7515 is 90 units for practitioner claims (Medicare: 0) and 600 units for DME supplier claims (Medicare: 1800). Compare both programs in the MUE lookup or read how Medicaid NCCI differs from Medicare.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J7515 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J7515 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J7515 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J7515 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J7515

1 active Local Coverage Determination lists J7515 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J7515 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J7515 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J7515 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J7515

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J7515

What does HCPCS code J7515 describe?

J7515 is defined by CMS as "Cyclosporine, oral, 25 mg". Each billing unit represents 25 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J7515 a CPT code?

No. J7515 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as cyclosporine; CPT codes are five-character codes maintained by the AMA. On a Part B claim J7515 reports the drug itself in 25 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J7515 in October 2026?

The ASP-based payment limit is $0.576 per 25 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.552. Commercial payers use their own fee schedules.

How many units of J7515 can be billed per day?

The practitioner Medically Unlikely Edit is 0 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). The facility outpatient MUE is 90. MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Oral Medication; Not Payable" as the rationale.

Which NDCs map to J7515?

The October 2026 ASP crosswalk lists 10 NDCs from 6 labelers: Gengraf (AbbVie Inc.); Sandimmune (Novartis Pharmaceuticals Corporation); Neoral (Novartis Pharmaceuticals Corporation); Cyclosporine (Teva Pharmaceuticals USA, Inc.). For example NDC 00074-3108-32 (package size 30) equals 30 billing units of J7515.

Does J7515 have NCCI bundling edits?

No active practitioner PTP pairs list J7515 as a column-1 or column-2 code in the v323r0 release.

J7515 vs J7516: what is the difference?

Both are HCPCS Level II codes whose descriptor names cyclosporine. What sets J7516 apart: billed per 250 mg. J7515 is billed per 25 mg, limit $0.576, MUE 0; J7516 is billed per 250 mg, limit $75.649, MUE 1. Report the code whose descriptor matches the product and setting in the record.

J7515 vs J7502: what is the difference?

Both are HCPCS Level II codes whose descriptor names cyclosporine. What sets J7502 apart: billed per 100 mg. J7515 is billed per 25 mg, limit $0.576, MUE 0; J7502 is billed per 100 mg, limit $1.455, MUE 0. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.